Compare Heron Therapeutics Inc (HRTX) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs CarMax, Inc — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while CarMax, Inc trades at $54 (market cap $7.64B). The key difference: CarMax, Inc is far larger — about 112.3× Heron Therapeutics Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and CarMax, Inc for 49 Days on average.
| HRTX | KMX | |
|---|---|---|
Market Cap | $68.01M | $7.64B |
Volume | 1,891,941 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $64.22 |
52-Week Low | $0.27 | $30.88 |
Typical Hold Time | 35 Days | 49 Days |
Enterprise Value | $174.75M | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
CarMax (KMX) trades at $53.28, down 3.64% amid a bearish technical signal, though recent Q2 2027 earnings beat estimates with EPS of $1.16 versus $0.732 expected. The company reported 19.5% revenue growth to $7.9 billion, driven by strong unit sales and cost control. Analyst consensus is mixed with 29.73% buy ratings and a $58.89 price target, while technical indicators show support at $52-$53 and resistance at $54.
The outlook is cautiously optimistic as CarMax's turnaround strategy shows early traction, but high debt levels and thin net margins near 1% pose risks. Near-term catalysts include the November strategic update, though macroeconomic pressures on consumer spending could challenge sustained growth. The stock offers value with a P/S of 0.28, but investors should monitor execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
